Standigm

Standigm is an AI-driven drug discovery company dedicated to accelerating and transforming the pharmaceutical R&D process. Leveraging state-of-the-art artificial intelligence, Standigm supports biotechnology and pharmaceutical organizations at critical stages of drug development, from identifying novel therapeutic targets to optimizing lead compounds with diverse and demanding property profiles.

The company positions itself as a pioneer in first-in-class target identification, helping partners uncover groundbreaking biological targets for innovative therapies. Standigm also brings deep expertise in comprehensive lead optimization, enabling drug discovery teams to refine candidate molecules across a broad range of physicochemical, pharmacokinetic, and biological properties.

Core Capabilities

• First-in-class target identification: Standigm applies advanced AI methodologies to discover novel, previously unexplored therapeutic targets, supporting the development of truly innovative medicines.
• Comprehensive lead optimization: The platform excels at guiding medicinal chemistry efforts to optimize lead compounds across multiple, diverse molecular properties simultaneously.
• AI SaaS and API solutions: Standigm offers cutting-edge artificial intelligence capabilities delivered as Software-as-a-Service (SaaS) and via API integrations, making its technology accessible and embeddable within partner workflows and existing drug discovery pipelines.

Technology and Platform

• Standigm provides state-of-the-art AI solutions purpose-built for drug discovery, combining proprietary machine learning models with deep domain expertise in life sciences.
• StandigmGPT is featured as a dedicated AI tool within the platform, reflecting the company's investment in large language model and generative AI capabilities for pharmaceutical research.
• The platform is designed to serve both internal research teams and external partners through flexible SaaS and API deployment models, enabling broad integration across the drug discovery ecosystem.

Company Profile and Reach

• Standigm operates with a bilingual presence, serving both English- and Korean-speaking markets, reflecting its roots and operations in Korea alongside its global ambitions.
• The company engages with the broader life sciences community through newsletters, publications, and industry insights, keeping partners and stakeholders informed of advances in AI-driven drug R&D.
• Standigm maintains a strong commitment to data privacy and security, implementing organizational, technical, and physical safeguards to protect all information handled through its platform and website.

Standigm's mission is to redefine the boundaries of drug discovery by making AI an indispensable partner in the identification of novel targets and the optimization of therapeutic candidates, ultimately helping bring more innovative medicines to patients faster.